![Surgical Science Sweden, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/8e06c9bb-6d85-440c-8530-67a9eec5162b.png)
Log in to your Inderes Free account to see all free content on this page.
Surgical Science Sweden
132 SEK +0.76%13 investors are following this company
Surgical Science Sweden is a medical technology company. The company develops VR simulators in surgery. The simulators consist of both hardware and software used in training and personal development by surgeons. The hardware simulates various surgical procedures, with mainly use in peephole surgery and endoscopy. The vision is to strengthen the competence in surgery and create conditions for better treatments. The company is headquartered in Gothenburg.
Revenue
-
EBIT %
-
P/E
28.76
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
SUS
Daily low / high price
128.4 / 135
SEK
Market cap
6.74B SEK
Turnover
44.99M SEK
Volume
346K
Latest videos
Financial calendar
Interim report
22.08.2024
Interim report
14.11.2024
Annual report
19.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Marknadspotential AB | 14.0 % | 14.0 % |
Roland Bengtsson | 11.7 % | 11.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
![Surgical Science Sweden, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/8e06c9bb-6d85-440c-8530-67a9eec5162b.png)
Tom Englund appointed new CEO of Surgical Science
Report from the Annual General Meeting of Surgical Science Sweden AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Redeye: Surgical Science Q1 2024 - Soft streak continues
![Surgical Science Sweden, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/9b93822a-daa1-4954-84ab-15c01f3e9276.png)
Surgical Science Sweden, Audiocast with teleconference, Q1, 2024
Interim report January – March 2024: PROPRIETARY SIMULATORS WEAK, INDUSTRIAL SEGMENT STRONG
Conference call regarding interim report Q1
Annual Report 2023
Notice of annual general meeting in SURGICAL SCIENCE SWEDEN AB (publ)
Gisli Hennermark to be nominated to Surgical Science's board
CEO Gisli Hennermark will leave Surgical Science in March 2025
Redeye: Surgical Science Sweden Q4 2023 - Long-term high quality, short-term black box
![Surgical Science Sweden, Audiocast with teleconference, Q4, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/44913eee-7260-4ded-8eaf-cd8a6e266c7b.png)
Surgical Science Sweden, Audiocast with teleconference, Q4, 2023
Year-end report 2023: STRONG LICENSE REVENUE, WEAKER SIMULATOR SALES
Conference call regarding Year-end Report 2023
Exercise of options against Surgical Science's two largest shareholders
Surgical Science changes Certified Adviser to Carnegie Investment Bank AB (publ)
Redeye: Surgical Science Q3 2023 - Weak growth, margins continued expanding
![Surgical Science, Audiocast with teleconference, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/0899efa6-f734-47da-a0af-6760f7a8a5eb.png)